Related Experiment Videos

Increased susceptibility to cephamycin-type antibiotics of methicillin-resistant Staphylococcus aureus defective in

K Murakami1, K Nomura, M Doi

  • 1Shionogi Research Laboratories, Shionogi and Co., Ltd., Osaka, Japan.

Insights

Methicillin-resistant Staphylococcus aureus lost a key protein (PBP 2) at high temperatures. This loss increased susceptibility to certain antibiotics targeting PBP 4, suggesting dual inhibition is needed to kill these resistant bacteria.

Area of Science:

  • Microbiology
  • Antibiotic Resistance
  • Molecular Biology

Background:

  • Methicillin-resistant Staphylococcus aureus (MRSA) poses a significant threat due to its resistance to beta-lactam antibiotics.
  • Penicillin-binding proteins (PBPs) are crucial targets for beta-lactam antibiotics, with PBP 2' being a key factor in MRSA resistance.
  • Understanding the mechanisms of MRSA resistance and identifying novel therapeutic targets is critical.

Purpose of the Study:

  • To investigate the stability and function of penicillin-binding protein 2' (PBP 2') in MRSA under varying temperature conditions.
  • To explore the susceptibility of MRSA mutants to beta-lactam antibiotics targeting different PBPs.
  • To identify potential synergistic therapeutic strategies against MRSA.

Main Methods:

  • Cultivation of a methicillin-resistant Staphylococcus aureus strain producing low-affinity PBP 2' at elevated temperatures (43°C).
  • Assessment of PBP 2' expression and stability in the cultivated strains.
  • Evaluation of the susceptibility of the resulting mutant strains to cephamycin-type beta-lactams at 37°C.

Main Results:

  • A MRSA strain spontaneously lost PBP 2' when cultured at 43°C.
  • The PBP 2'-deficient mutant exhibited increased susceptibility to cephamycin-type beta-lactams at 37°C.
  • These beta-lactams demonstrated high affinity for penicillin-binding protein 4 (PBP 4).

Conclusions:

  • The loss of PBP 2' under specific conditions can alter MRSA susceptibility to certain antibiotics.
  • Inhibition of PBP 4, in conjunction with PBP 2', may be a necessary strategy to effectively kill MRSA.
  • This finding suggests a potential dual-target approach for developing new MRSA therapies.

Related Concept Videos